FrancophonIA/ELRC3.0 huggingface dataset:
English: Co-administration with EVOTAZ has the potential to produce serious and/or life-threatening bleeding due to increased exposure to warfarin and has not been studied.
Slovenian: Pri sočasni uporabi zdravila EVOTAZ se lahko pojavijo resne in/ali smrtno nevarne krvavitve zaradi povečane izpostavljenosti varfarinu.
English: Co-administration of EVOTAZ and elbasvir/grazoprevir is contraindicated because of the expected increase in grazoprevir plasma concentrations and the associated potential increase in the risk of ALT elevations (see section 4.3).
Slovenian: Sočasna uporaba zdravila EVOTAZ in elbasvirja/grazoprevirja je kontraindicirana zaradi pričakovanega povečanja koncentracij grazoprevirja v plazmi in s tem povezanega možnega večjega tveganja za zvišanje vrednosti ALT (glejte poglavje 4.3).
English: There were no tumorigenic findings in male mice or in rats.
Slovenian: Pri samcih miši ali podgan tumorogenih sprememb niso odkrili.
English: Co-administration with EVOTAZ has the potential to produce serious and/or life-threatening adverse reactions.
Slovenian: Pri sočasni uporabi zdravila EVOTAZ se lahko pojavijo resni in/ali smrtno nevarni neželeni učinki.
English: (atazanavir 300 mg once daily with cobicistat 150 mg once daily)
Slovenian: (atazanavir 300 mg enkrat na dan s kobicistatom 150 mg enkrat na dan)
English: If you feel dizzy or lightheaded, please contact your doctor immediately.
Slovenian: V primeru omotice ali vrtoglavice se nemudoma posvetujte z zdravnikom.
English: Because atazanavir is a component of EVOTAZ, co-administration of EVOTAZ with nevirapine or efavirenz is not recommended (see section 4.5).
Slovenian: Zdravilo EVOTAZ vsebuje atazanavir, zato sočasna uporaba zdravila EVOTAZ in nevirapina ali efavirenza ni priporočljiva (glejte poglavje 4.5).
English: Tenofovir disoproxil fumarate (tenofovir DF) 300 mg once daily (atazanavir 400 mg once daily)
Slovenian: Dizoproksiltenofovirijev fumarat (tenofovir DF) 300 mg enkrat na dan (atazanavir 400 mg enkrat na dan)
English: For more information consult the cobicistat Summary of Product Characteristics.
Slovenian: Za več informacij glejte povzetek glavnih značilnosti zdravila za kobicistat.
English: In study GS-US-216-0114, the mean increase from baseline in CD4+ cell count at weeks 48 and 144 were 213 and 310 cells/mm3 in patients receiving atazanavir boosted with cobicistat and 219 and 332 cells/mm3 in patients receiving atazanavir boosted with ritonavir, respectively.
Slovenian: V študiji GS-US-216-0114 je povprečno povečanje števila celic CD4+ od izhodišča pri bolnikih, ki so prejemali atazanavir, okrepljen s kobicistatom, v 48. tednu znašalo 213 celic/mm3, v 144. tednu pa 310 celic/mm3.
English: Co-administration of EVOTAZ and these antiepileptics is contraindicated (see section 4.3).
Slovenian: Sočasna uporaba zdravila EVOTAZ in teh antiepileptikov je kontraindicirana (glejte poglavje 4.3).
English: The mechanism of interaction is inhibition of CYP3A4 and/or CYP2D6 by atazanavir and/or cobicistat.
Slovenian: Mehanizem interakcije je zaviranje CYP3A4 in/ali CYP2D6 z atazanavirjem in/ali kobicistatom.
English: Atazanavir has been studied in adult patients with severe renal impairment (n=20), including those on haemodialysis, at multiple doses of 400 mg once daily.
Slovenian: Uporabo atazanavirja so raziskovali pri odraslih bolnikih s hudo okvaro ledvic (n=20), vključno z bolniki, ki so se zdravili s hemodializo.
English: Drospirenone/ethinyloestradiol 3 mg/0.02 mg single dose (atazanavir 300 mg once daily with cobicistat 150 mg once daily)
Slovenian: Drospirenon/etinilestradiol 3 mg/0,02 mg enkratni odmerek (atazanavir 300 mg enkrat na dan s kobicistatom 150 mg enkrat na dan)
English: CORTICOSTEROIDS
Slovenian: KORTIKOSTEROIDI
English: Neither metabolite demonstrated in vitro antiviral activity.
Slovenian: Nobeden od presnovkov in vitro ni imel protivirusnega učinka.
English: Rifabutin 150 mg every other day/elvitegravir 150 mg once daily/cobicistat 150 mg once daily
Slovenian: Rifabutin 150 mg vsak drugi dan/elvitegravir 150 mg enkrat na dan/kobicistat 150 mg enkrat na dan
English: EVOTAZ must not be used in patients with moderate to severe hepatic impairment (see section 4.3).
Slovenian: Pri bolnikih z zmerno do hudo okvaro jeter se zdravila EVOTAZ ne sme uporabljati (glejte poglavje 4.3).
English: Maraviroc is not expected to have an impact on concentrations of atazanavir and cobicistat.
Slovenian: Vpliva maraviroka na koncentracije atazanavirja in kobicistata ni pričakovati.
English: Atazanavir should be used with caution in patients with mild (Child-Pugh Class A) hepatic impairment.
Slovenian: Pri bolnikih z blago (Child-Pugh A) okvaro jeter je treba atazanavir uporabljati previdno, pri bolnikih z zmerno (Child-Pugh B) do hudo (Child-Pugh C) okvaro jeter pa se atazanavirja ne sme uporabljati.
English: Stevens-Johnson syndrome (SJS), erythema multiforme, toxic skin eruptions and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome have been reported with the use of atazanavir (see section 4.4).
Slovenian: Pri bolnikih, ki so se zdravili z atazanavirjem, so poročali o pojavu Stevens-Johnsonovega sindroma, multiformnega eritema, toksičnih izbruhov na koži in sindroma medikamentoznega izpuščaja z eozinofilijo in s sistemskimi simptomi (DRESS) (glejte poglavje 4.4).
English: How to store EVOTAZ
Slovenian: Kako jemati zdravilo EVOTAZ
English: The mechanism of interaction is inhibition of P-gp by cobicistat.
Slovenian: Mehanizem interakcije je zaviranje P-gp s kobicistatom.
English: Cobicistat has been shown to decrease estimated creatinine clearance due to inhibition of tubular secretion of creatinine.
Slovenian: Dokazano je bilo, da kobicistat zmanjša ocenjeni kreatininski očistek, kar je posledica zaviranja tubulne sekrecije kreatinina.
English: No teratogenic effects were observed in rats and rabbit developmental toxicity studies.
Slovenian: V študijah vplivov na razvoj pri podganah in kuncih niso opazili teratogenih učinkov.
English: The active substances are atazanavir and cobicistat.
Slovenian: Učinkovini sta atazanavir in kobicistat.
English: The mechanism of interaction is CYP3A4 inhibition by atazanavir, cobicistat and ketoconazole or itraconazole.
Slovenian: Mehanizem interakcije je zaviranje CYP3A4 z atazanavirjem, kobicistatom in ketokonazolom ali itrakonazolom.
English: Omeprazole 40 mg once daily (atazanavir 400 mg once daily, 2 hours after omeprazole)
Slovenian: Omeprazol 40 mg enkrat na dan (atazanavir 400 mg enkrat na dan, 2 uri po omeprazolu)
English: Co-administration of etravirine and EVOTAZ is expected to decrease atazanavir and cobicistat plasma concentrations.
Slovenian: Pri sočasni uporabi etravirina in zdravila EVOTAZ pričakujemo zmanjšanje koncentracij atazanavirja in kobicistata v plazmi.
English: Co-administration of salmeterol with EVOTAZ is not recommended (see section 4.4).
Slovenian: Sočasna uporaba salmeterola in zdravila EVOTAZ ni priporočljiva (glejte poglavje 4.4).
English: With Tenofovir DF 300 mg once daily Famotidine 20 mg twice daily (atazanavir 300 mg/ritonavir 100 mg/tenofovir DF 300 mg once daily, simultaneous administration)
Slovenian: S tenofovirjem DF v odmerku 300 mg enkrat na dan Famotidin 20 mg dvakrat na dan (atazanavir 300 mg/ritonavir 100 mg/tenofovir DF 300 mg enkrat na dan, sočasna uporaba)
English: Effect of cobicistat on atazanavir pharmacokinetics
Slovenian: Vpliv kobicistata na farmakokinetiko atazanavirja
English: Because atazanavir is a component of EVOTAZ, the combination of EVOTAZ with atorvastatin is not recommended (see section 4.5).
Slovenian: Zdravilo EVOTAZ vsebuje atazanavir, zato zdravila EVOTAZ ni priporočljivo uporabljati v kombinaciji z atorvastatinom (glejte poglavje 4.5).
English: Atazanavir and fluconazole concentrations were not significantly modified when atazanavir/ritonavir was co-administered with fluconazole.
Slovenian: Pri sočasni uporabi atazanavirja/ritonavirja in flukonazola se koncentracije atazanavirja in flukonazola niso pomembneje spremenile.
English: Patients should not breast-feed while taking EVOTAZ.
Slovenian: Bolnice med zdravljenjem z zdravilom EVOTAZ ne smejo dojiti.
English: Hepatic transaminase elevations that occur with elevated bilirubin in patients receiving EVOTAZ should be evaluated for alternative etiologies.
Slovenian: Če se pri bolniku, ki se zdravi z zdravilom EVOTAZ, pojavi zvišanje vrednosti jetrnih aminotransferaz, ki jih spremlja zvišanje vrednosti bilirubina, je treba ugotoviti morebitne druge vzroke.
English: Atazanavir demonstrates nonlinear pharmacokinetics with greater than dose-proportional increases in AUC and Cmax values over the dose range of 200 mg to 800 mg once daily.
Slovenian: V razponu odmerkov od 200 mg do 800 mg enkrat na dan se vrednosti AUC in Cmax povečajo bolj kot proporcionalno z odmerkom.
English: Clinical monitoring is recommended upon co-administration with EVOTAZ.
Slovenian: Pri sočasni uporabi zdravila EVOTAZ priporočamo klinični nadzor.
English: Uncommon (may affect up to 1 in 100 people) torsade de pointes (life threatening irregular heart beat) hypersensitivity (allergic reaction) anorexia (loss of appetite), weight loss, weight gain depression, anxiety, sleep disorder disorientation, amnesia (loss of memory) peripheral neuropathy (numbness, weakness, tingling or pain in the arms and legs) syncope (fainting), hypertension (high blood pressure) dyspnoea (shortness of breath) pancreatitis (inflammation of the pancreas), gastritis (inflammation of the stomach), stomatitis aphthous (mouth ulcers and cold sores) hepatitis (inflammation of the liver) angioedema (severe swelling of the skin and other tissues most often the lips or the eyes) urticaria (itchy rash), alopecia (unusual hair loss or thinning), pruritus (itching) muscle atrophy (muscle shrinkage), arthralgia (joint pain), myalgia (aching muscles) nephrolithiasis (formation of kidney stones), interstitial nephritis (kidney inflammation), hematuria (blood in the urine), proteinuria (excess protein in the urine), pollakiuria (increased frequency of urination), chronic kidney disease (how well your kidneys work) gynaecomastia (breast enlargement in men) chest pain, malaise (generally feeling unwell), fever asthenia (unusual tiredness or weakness) serious skin rashes (allergic reactions including rash, a high temperature, increased levels of liver enzymes seen in blood tests, an increase in a type of white blood cell [esosinophilia] and/or enlarged lymph nodes) (see section 2) gallbladder disorders (gallstones and gallbladder inflammation)
Slovenian: angioedem (hudo otekanje kože in drugih tkiv, najpogosteje ustnic ali oči) koprivnica (srbeč kožni izpuščaj), alopecija (neobičajno izpadanje ali redčenje las), pruritus (srbenje) mišična atrofija (zmanjšanje mišične mase), artralgija (bolečina v sklepu), mialgija (bolečina v mišicah) nefrolitiaza (nastanek ledvičnih kamnov), intersticijski nefritis (vnetje ledvic), hematurija (kri v urinu), proteinurija (presežek beljakovin v urinu), polakisurija (pogosto uriniranje), kronična ledvična bolezen (kako dobro delujejo vaše ledvice) ginekomastija (povečanje dojk pri moških) bolečine v prsnem košu, splošno slabo počutje, zvišana telesna temperatura astenija (neobičajna utrujenost ali oslabelost) resni kožni izpuščaji (alergijska reakcija s kožnim izpuščajem, zvišano telesno temperaturo, zvišano vrednostjo jetrnih encimov, ugotovljenih pri krvnih preiskavah, povečanjem števila določene vrste belih krvnih celic [eozinofilija] in/ali povečanjem bezgavk) (glejte poglavje 2) bolezni žolčnika (žolčni kamni in vnetje žolčnika)
English: It is not recommended to co-administer EVOTAZ with simeprevir.
Slovenian: Zdravila EVOTAZ ni priporočljivo uporabljati skupaj s simeprevirjem.
English: There are no pharmacokinetic data available for atazanavir in combination with cobicistat in patients with renal insufficiency.
Slovenian: Farmakokinetični podatki o uporabi atazanavirja v kombinaciji s kobicistatom pri bolnikih z okvaro delovanja ledvic niso na voljo.
English: Efavirenz 600 mg single dose (cobicistat 150 mg once daily)
Slovenian: Efavirenz 600 mg enkratni odmerek (kobicistat 150 mg enkrat na dan)
English: Cobicistat is not expected to inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9 or CYP2C19.
Slovenian: Ne pričakujemo, da bi kobicistat zaviral CYP1A2, CYP2B6, CYP2C8, CYP2C9 ali CYP2C19.
English: ANTIBIOTICS Clarithromycin 500 mg twice daily (atazanavir 400 mg once daily)
Slovenian: Klaritromicin 500 mg dvakrat na dan (atazanavir 400 mg enkrat na dan)
English: Co-administration of EVOTAZ with glecaprevir/pibrentasvir fixed dose combination is contraindicated because of the potential increase in the risk of ALT elevations due to a significant increase in glecaprevir and pibrentasvir plasma concentrations (see section 4.3).
Slovenian: Sočasna uporaba zdravila EVOTAZ in fiksne kombinacije glekaprevir/pibrentasvir je kontraindicirana zaradi možnega večjega tveganja za zvišanje vrednosti ALT zaradi pomembnega povečanja koncentracij glekaprevirja in pibrentasvirja v plazmi (glejte poglavje 4.3).
English: For medicinal products metabolised by CYP3A these higher plasma concentrations may potentially lead to severe, life-threatening or fatal events (see sections 4.3 and 4.5).
Slovenian: Zaradi povečanja plazemskih koncentracij sočasno uporabljenih zdravil, ki se presnavljajo s CYP3A, se lahko okrepijo ali podaljšajo terapevtski učinki teh zdravil ali pojavijo njihovi neželeni učinki, vključno s hudimi, smrtno nevarnimi ali usodnimi dogodki (glejte poglavji 4.3 in 4.5).
English: The demographic and baseline characteristics were similar between the atazanavir with cobicistat and atazanavir with ritonavir groups.
Slovenian: Demografske lastnosti bolnikov in izhodiščne značilnosti bolezni so bile v skupini, ki je prejemala atazanavir s kobicistatom, podobne kot v skupini, ki je prejemala atazanavir z ritonavirjem.
English: No clinically relevant pharmacokinetic differences due to gender have been identified for atazanavir or cobicistat.
Slovenian: Klinično pomembnih razlik v farmakokinetiki atazanavirja ali kobicistata glede na spol niso ugotovili.
English: Vascular disorders uncommon hypertension
Slovenian: Žilne bolezni občasni hipertenzija
English: Adverse Reactions uncommon myalgia, muscle atrophy, arthralgia rare myopathy
Slovenian: Bolezni mišično-skeletnega sistema in vezivnega tkiva občasni mialgija, mišična atrofija, artralgija redki miopatija
English: The mechanism of interaction is CYP3A and/or P-glycoprotein inhibition by atazanavir and cobicistat.
Slovenian: Mehanizem interakcije je zaviranje CYP3A in/ali P-glikoproteina z atazanavirjem in kobicistatom.
English: Naloxone AUC: ↓28% Naloxone Cmax: ↓28%
Slovenian: Nalokson AUC: ↓28% Nalokson Cmax: ↓28%
English: Stevens-Johnson syndrome (SJS), erythema multiforme, toxic skin eruptions and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome have been reported in patients receiving atazanavir.
Slovenian: Pri bolnikih, ki so se zdravili z atazanavirjem, so poročali o pojavu Stevens-Johnsonovega sindroma, multiformnega eritema, toksičnih izbruhov na koži in sindroma medikamentoznega izpuščaja z eozinofilijo in sistemskimi simptomi (DRESS; “drug rash with eosinophilia and systemic symptoms”).
English: EVOTAZ is expected to increase rilpivirine plasma concentrations.
Slovenian: Pričakovati je, da bo zdravilo EVOTAZ povečalo koncentracije rilpivirina v plazmi.
English: The co-administration of EVOTAZ with stavudine is not expected to significantly alter the exposure of stavudine.
Slovenian: Pri sočasni uporabi zdravila EVOTAZ s stavudinom pomembnejših sprememb v izpostavljenosti stavudinu ne pričakujemo.
English: The effects of hepatic impairment on the pharmacokinetics of atazanavir given with cobicistat have not been studied.
Slovenian: Vpliva okvare jeter na farmakokinetiko atazanavirja pri uporabi skupaj s kobicistatom niso raziskovali.
English: The mechanism of interaction is CYP3A inhibition.
Slovenian: Mehanizem interakcije je zaviranje CYP3A.
English: The mechanism of interaction is CYP3A4 and UGT1A1 inhibition by atazanavir.
Slovenian: Mehanizem interakcije je zaviranje CYP3A4 in UGT1A1 z atazanavirjem.
English: EVOTAZ is expected to increase simeprevir plasma concentrations.
Slovenian: Pričakovati je, da bo zdravilo EVOTAZ povečalo koncentracije simeprevirja v plazmi.
English: Telaprevir 750 mg three times daily (atazanavir/ritonavir 300/100 mg once daily)
Slovenian: Telaprevir 750 mg trikrat na dan (atazanavir/ritonavir 300/100 mg enkrat na dan)
English: Alternative corticosteroids which are less dependent on CYP3A metabolism, e.g. beclomethasone for intranasal or inhalational use, should be considered, particularly for long term use.
Slovenian: Zlasti pri dolgotrajni uporabi je treba premisliti o uporabi drugih kortikosteroidov, ki so manj odvisni od presnove s pomočjo encimov CYP3A, npr. beklometazona za intranazalno uporabo ali inhaliranje.
English: Co-administration of EVOTAZ with astemizole and terfenadine is contraindicated (see section 4.3).
Slovenian: Sočasna uporaba zdravila EVOTAZ in astemizola ali terfenadina je kontraindicirana (glejte poglavje 4.3).
English: More frequent therapeutic concentration monitoring is recommended for immunosuppressant agents when co-administered with EVOTAZ.
Slovenian: Pri sočasni uporabi zdravila EVOTAZ priporočamo pogostejše nadziranje terapevtskih koncentracij imunosupresivov.
English: The mechanism of interaction is P-gp inhibition by atazanavir and cobicistat.
Slovenian: Mehanizem interakcije je zaviranje P-gp z atazanavirjem in kobicistatom.
English: No clinically relevant pharmacokinetic differences due to ethnicity have been identified for atazanavir or cobicistat.
Slovenian: Klinično pomembnih razlik v farmakokinetiki atazanavirja ali kobicistata glede na etnično pripadnost niso ugotovili.
English: A decrease in the dose of neuroleptics metabolized by CYP3A or CYP2D6 may be required when co-administered with EVOTAZ.
Slovenian: Pri sočasni uporabi zdravila EVOTAZ bo morda treba zmanjšati odmerek nevroleptikov, ki se presnavljajo s CYP3A ali CYP2D6.
English: The mechanism of interaction is induction of CYP3A4 by bosentan.
Slovenian: Mehanizem interakcije je indukcija CYP3A4 z bosentanom.
English: The mechanism of interaction is CYP3A4 induction by etravirine.
Slovenian: Mehanizem interakcije je indukcija CYP3A4 z etravirinom.
English: The mechanism of interaction is a reduced solubility of atazanavir with increasing pH related to the presence of anti-acid agent in didanosine buffered tablets.
Slovenian: Mehanizem te interakcije je manjša topnost atazanavirja pri višjem pH-ju zaradi antacidnega sredstva v pufranih tabletah didanozina.
English: The mechanism of interaction is inhibition of UGT1A1 by atazanavir.
Slovenian: Mehanizem interakcije je zaviranje UGT1A1 z atazanavirjem.
English: Atazanavir with cobicistatf (n = 344)
Slovenian: 144. teden Atazanavir s Atazanavir z Atazanavir s Atazanavir z kobicistatomf (n = 344)
English: Concentrations of these sedatives/hypnotics may be increased when co-administered with EVOTAZ.
Slovenian: Pri sočasni uporabi zdravila EVOTAZ se koncentracije teh sedativov/hipnotikov lahko povečajo.
English: Tablet core - microcrystalline cellulose (E460(i)), croscarmellose sodium (E468), sodium starch glycolate, crospovidone (E1202), stearic acid (E570), magnesium stearate (E470b), hydroxypropyl cellulose (E463), silicon dioxide (E551) Film-coating - hypromellose (hydroxypropyl methyl cellulose, E464), titanium dioxide (E171), talc (E553b), triacetin (E1518), red iron oxide (E172)
Slovenian: Jedro tablete - mikrokristalna celuloza (E460(i)), premreženi natrijev karmelozat (E468), natrijev karboksimetilškrob, krospovidon (E1202), stearinska kislina (E570), magnezijev stearat (E470b), hidroksipropilceluloza (E463) in silicijev dioksid (E551).
English: EVOTAZ is not recommended for co-administration with efavirenz.
Slovenian: Zdravila EVOTAZ ni priporočljivo uporabljati skupaj z efavirenzem.
English: EVOTAZ is a fixed-dose combination of the antiviral drug atazanavir boosted by the pharmacokinetic enhancer cobicistat.
Slovenian: Zdravilo EVOTAZ je fiksna kombinacija odmerkov protivirusne učinkovine atazanavirja in ojačevalca farmakokinetike kobicistata.
English: Co-administration of EVOTAZ with proton pump inhibitors is not recommended.
Slovenian: Sočasna uporaba zdravila EVOTAZ in zaviralcev protonske črpalke ni priporočljiva.
English: Dihydroergotamine Ergometrine Ergotamine Methylergonovine
Slovenian: Dihidroergotamin Ergometrin Ergotamin Metilergonovin
English: There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses, in type A and B haemophiliac patients treated with protease inhibitors.
Slovenian: Pri bolnikih s hemofilijo A ali B, ki so se zdravili z zaviralci proteaz, so poročali o pogostejših krvavitvah, vključno s spontanimi kožnimi hematomi in hemartrozami.
English: The mechanism of interaction is decreased solubility of atazanavir as intra-gastric pH increases with proton pump inhibitors.
Slovenian: Mehanizem interakcije je manjša topnost atazanavirja pri zvišani pH vrednosti želodčne vsebine zaradi uporabe zaviralcev protonske črpalke.
English: Dose related asymptomatic prolongations in PR interval with atazanavir, a component of EVOTAZ have been observed in clinical studies.
Slovenian: Pri zdravljenju z atazanavirjem, sestavino zdravila EVOTAZ, so v kliničnih študijah poročali o od odmerka odvisnem asimptomatskem podaljšanju intervala PR.
English: The mechanism is UGT1A1 inhibition by atazanavir.
Slovenian: Mehanizem je zaviranje UGT1A1 z atazanavirjem.
English: The mechanism of interaction is CYP3A4 induction by rifampicin.
Slovenian: Mehanizem interakcije je indukcija CYP3A4 z rifampicinom.
English: EVOTAZ or any other medicinal product containing atazanavir should be discontinued if severe rash develops.
Slovenian: V primeru pojava hudega kožnega izpuščaja je treba zdravljenje z zdravilom EVOTAZ ali s katerim koli drugim zdravilom, ki vsebuje atazanavir, prekiniti.
English: ANTINEOPLASTICS AND IMMUNOSUPRESSANTS
Slovenian: ZDRAVILA Z DELOVANJEM NA NOVOTVORBE IN IMUNOSUPRESIVI
English: Co-administration of neuroleptics with EVOTAZ may result in increased plasma concentrations of neuroleptics.
Slovenian: Pri sočasni uporabi nevroleptikov in zdravila EVOTAZ se koncentracije nevroleptikov v plazmi lahko povečajo.
English: Rilpivirine
Slovenian: Rilpivirin
English: Lamivudine 150 mg twice daily + zidovudine 300 mg twice daily (atazanavir 400 mg once daily)
Slovenian: Lamivudin 150 mg dvakrat na dan + zidovudin 300 mg dvakrat na dan (atazanavir 400 mg enkrat na dan)
English: Glecaprevir 300 mg/pibrentasvir 120 mg once daily (atazanavir 300 mg with ritonavir 100 mg once daily*)
Slovenian: 300 mg/pibrentasvir 120 mg enkrat na dan (atazanavir 300 mg z ritonavirjem 100 mg enkrat na dan*)
English: Coadministration of EVOTAZ with voxilaprevir-containing regimens is not recommended.
Slovenian: Sočasna uporaba zdravila EVOTAZ in zdravil, ki vsebujejo voksilaprevir, ni priporočljiva.
English: The mechanism of interaction is CYP3A4 induction by nevirapine and CYP3A4 inhibition by atazanavir and cobicistat.
Slovenian: Mehanizem interakcije je indukcija CYP3A4 z nevirapinom in zaviranje CYP3A4 z atazanavirjem in kobicistatom.
English: Stevens-Johnson syndrome (allergic reactions including serious skin rash, a high temperature and enlarged lymph nodes) (see section 2).
Slovenian: Stevens-Johnsonov sindrom (alergijska reakcija s hudim kožnim izpuščajem, zvišano telesno temperaturo in povečanjem bezgavk) (glejte poglavje 2) miopatija (bolečina, občutljivost ali oslabelost mišic, ki ni posledica telesnega napora) bolečina v ledvicah
English: Cobicistat:
Slovenian: Kobicistat:
English: Caution is warranted and therapeutic concentration monitoring of these medicinal products is recommended if they are used concomitantly with EVOTAZ.
Slovenian: Priporočamo nadziranje terapevtskih koncentracij teh zdravil.